Baird analyst Brian Skorney said he was "incrementally negative" Gilead Sciences' (NASDAQ: GILD) acquisition of Kite Pharma (NASDAQ: KITE).Skorney said ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE